Supports intestinal health in adults and children:
- Provides live microorganisms that temporarily modify gut flora
- Provides 20 billion CFU per daily dose from: Lactobacillus acidophilus (CUL-60), Lactobacillus acidophilus (CUL-21), Bifidobacterium bifidum (CUL-20), Bifidobacterium animalis subsp. lactis (CUL-34)
HMF Forte is a combination of four strains of proprietary human-sourced probiotics that help promote gastrointestinal health in adults and children. Supplementation with large numbers of a combination of microorganisms will help maximize intestinal colonization, promoting the growth of beneficial bacteria.1
In a randomized, placebo-controlled trial involving 22 adults, daily supplementation with a probiotic containing Lactobacillus acidophilus (CUL-60 and CUL-21) stimulated the restoration of microflora after it was altered by antibiotics.2
Likewise, research also demonstrates that a probiotic supplement containing CUL-21 can significantly colonize the gut of healthy adults.3
Lactobacilli and Bifidobacteria are the most commonly used probiotics, and are safe for both adults and children.4 They successfully colonize the intestines, increase the release of antimicrobial peptides from host cells, and decrease the proliferation of pathogens.4 Probiotics also control the permeability of epithelial cells by mediating tight junction formation, and prevent pathogenic adherence to cells by increasing mucin release on the intestinal surface.4
1. Allen, SJ, Wareham, K, Bradley, C, Harris, W, Dhar, A, Brown, H, Foden, A, Cheung, WY, Gravenor, MB, Plummer, S, Phillips, CJ, Mack, D. A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infectious Diseases. 2012; 12: 108.
2. Madden, JAJ, Plummer, SF, Tang, J, Garaiova, I, Plummer, NT, Herbison, M, Hunter, JO, Shimada, T, Cheng, L, Shirakawa, T. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: A double-blind, placebo-controlled pilot study. International Immunopharmacology. 2005; 5: 1091-1097.
3. Mahenthiralingam, E, Marchbank, A, Drevinek, P, Garaiova, I, Plummer, S. Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption. BMC Microbiology. 2009; 9: 251.